{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:42:20Z","timestamp":1776213740495,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2026.100311","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:44:56Z","timestamp":1772487896000},"page":"100311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preference versus protocol: oncology clinicians\u2019 perspectives on central venous access for administration of chemotherapy in pancreatic cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-1458","authenticated-orcid":false,"given":"M.U.J.E.","family":"Graus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5157-0191","authenticated-orcid":false,"given":"R.A.L.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2891-0553","authenticated-orcid":false,"given":"N.C.","family":"Biesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-1171","authenticated-orcid":false,"given":"A.J.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-9429","authenticated-orcid":false,"given":"S.A.W.","family":"Bouwense","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8712-9825","authenticated-orcid":false,"given":"G.A.","family":"Cirkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Y.V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jellema-Betten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pepels-Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"van Santvoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.J.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Wumkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.H.J.T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.B.J.","family":"Valkenburg-van Iersel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"J.","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmogo.2026.100311_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2026.100311_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/tgh.2019.04.04","article-title":"Adjuvant treatment for pancreatic cancer","volume":"4","author":"Klaiber","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.esmogo.2026.100311_bib5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100311_bib6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.esmogo.2026.100311_bib7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100311_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.esmogo.2026.100311_bib9","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100311_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/curroncol28010039","article-title":"Utilization and complications of central venous access devices in oncology patients","volume":"28","author":"Akhtar","year":"2021","journal-title":"Curr Oncol"},{"issue":"10298","key":"10.1016\/j.esmogo.2026.100311_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(21)00766-2","article-title":"Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial","volume":"398","author":"Moss","year":"2021","journal-title":"Lancet"},{"issue":"47","key":"10.1016\/j.esmogo.2026.100311_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25470","article-title":"Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT","volume":"25","author":"Wu","year":"2021","journal-title":"Health Technol Assess"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100311_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bja.2019.01.038","article-title":"Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial","volume":"122","author":"Taxbro","year":"2019","journal-title":"Br J Anaesth"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100311_bib14","article-title":"Peripherally inserted central venous catheters (PICC) versus totally implantable venous access device (PORT) for chemotherapy administration: a meta-analysis on gynecological cancer patients","volume":"92","author":"Capozzi","year":"2021","journal-title":"Acta Biomed"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100311_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.13767","article-title":"Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma","volume":"109","author":"P\u00e9nichoux","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100311_bib16","first-page":"121","article-title":"Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies","volume":"22","author":"Patel","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100311_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/1129729819895737","article-title":"Economic evaluation of peripherally inserted central catheter and other venous access devices: a scoping review","volume":"21","author":"Wang","year":"2020","journal-title":"J Vasc Access"},{"issue":"suppl 5","key":"10.1016\/j.esmogo.2026.100311_bib18","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"Sousa","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100311_bib19","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/SLA.0000000000003779","article-title":"Establishing and coordinating a nationwide multidisciplinary study group: lessons learned by the Dutch Pancreatic Cancer Group","volume":"271","author":"Strijker","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmogo.2026.100311_bib20","series-title":"(03-06-2019)","article-title":"Richtlijnendatabase: Pancreascarcinoom","author":"Specialisten","year":"2019"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100311_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234966","article-title":"Appropriate duration of peripherally inserted central catheter maintenance to prevent central line-associated bloodstream infection","volume":"15","author":"Park","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100311_bib22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.7150\/jca.103631","article-title":"Implantable port catheters versus peripherally inserted central catheters for cancer patients requiring chemotherapy: an RCT-based meta-analysis","volume":"16","author":"Qiu","year":"2025","journal-title":"J Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100311_bib23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jvsv.2022.03.007","article-title":"A systematic review and network meta-analysis of randomized controlled trials on choice of central venous access device for delivery of chemotherapy","volume":"10","author":"Yeow","year":"2022","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.esmogo.2026.100311_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.11.022","article-title":"Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer","volume":"126","author":"Clatot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmogo.2026.100311_bib25","first-page":"4891","article-title":"A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer","volume":"28","author":"Clemons","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100311_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/aas.13505","article-title":"Cost analysis comparison between peripherally inserted central catheters and implanted chest ports in patients with cancer - a health economic evaluation of the PICCPORT trial","volume":"64","author":"Taxbro","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.esmogo.2026.100311_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2024.104695","article-title":"Patient preferences and willingness to pay for central venous access devices in breast cancer: a multicenter discrete choice experiment","volume":"152","author":"Liu","year":"2024","journal-title":"Int J Nurs Stud"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100311_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-019-0510-x","article-title":"The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues","volume":"121","author":"Campello","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmogo.2026.100311_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjao.2022.100026","article-title":"Patient-controlled sedation in port implantation (PACSPI 1) \u2013 a feasibility trial","volume":"3","author":"Seifert","year":"2022","journal-title":"BJA Open"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100311_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1358863X16643602","article-title":"Sedation shared decision-making in ambulatory venous access device placement: effects on patient choice, satisfaction and recovery time","volume":"21","author":"Chittle","year":"2016","journal-title":"Vasc Med"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100311_bib31","first-page":"105","article-title":"Guidelines for Central Venous Port Placement and Management (Abridged Translation of the Japanese Version)","volume":"8","author":"Sugawara","year":"2023","journal-title":"Interv Radiol (Higashimatsuyama)"},{"issue":"9684","key":"10.1016\/j.esmogo.2026.100311_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(09)60220-8","article-title":"Management of occlusion and thrombosis associated with long-term indwelling central venous catheters","volume":"374","author":"Baskin","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.esmogo.2026.100311_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjao.2025.100377","article-title":"Peripherally inserted central catheters versus implanted port catheters in patients with breast cancer: a post hoc analysis of the PICCPORT randomised controlled trial","volume":"13","author":"Utas","year":"2025","journal-title":"BJA Open"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:44:26Z","timestamp":1776210266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S2949819826000117"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100311","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preference versus protocol: oncology clinicians\u2019 perspectives on central venous access for administration of chemotherapy in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100311"}}